FORODESINE
Forodesine is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against purine nucleoside phosphorylase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
14 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 4 | 7 | — | — | — | 8 |
| Lymphoid leukemia | D007945 | — | C91 | 4 | 6 | — | — | — | 7 |
| Lymphoma | D008223 | — | C85.9 | 4 | 5 | — | — | — | 6 |
| T-cell lymphoma | D016399 | — | — | 4 | 4 | — | — | — | 5 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | 2 | — | — | — | 3 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 2 | 3 | — | — | — | 3 |
| Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | — | — | 2 | 3 | — | — | — | 3 |
| T-cell lymphoma cutaneous | D016410 | — | — | 2 | 2 | — | — | — | 3 |
| Recurrence | D012008 | — | — | 2 | 1 | — | — | — | 2 |
| T-cell lymphoma peripheral | D016411 | — | — | 1 | 2 | — | — | — | 2 |
Show 3 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | FORODESINE |
| INN | forodesine |
| Description | Forodesine (INN; also known as Immucillin H; trade names Mundesine and Fodosine) is a transition-state analog inhibitor of purine nucleoside phosphorylase studied for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and for treatment of B-cell acute lymphocytic leukemia (B-ALL).
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=c1[nH]cnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12 |
Identifiers
| PDB | — |
| CAS-ID | 209799-67-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL218291 |
| ChEBI ID | 43362 |
| PubChem CID | 444499 |
| DrugBank | — |
| UNII ID | 426X066ELK (ChemIDplus, GSRS) |
Target
Agency Approved
PNP
PNP
Organism
Homo sapiens
Gene name
PNP
Gene synonyms
NP
NCBI Gene ID
Protein name
purine nucleoside phosphorylase
Protein synonyms
epididymis secretory sperm binding protein Li 156an, HEL-S-156an, Inosine phosphorylase, Inosine-guanosine phosphorylase, purine-nucleoside:orthophosphate ribosyltransferase
Uniprot ID
Mouse ortholog
Pnp (18950)
purine nucleoside phosphorylase (P23492)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 377 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
32 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use